Clinical trial · Observational
Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.
Evaluation of the Technical Feasibility of Testing Circulating Tumour DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.
NCT05415787CI-TRIAL-00074608PROMECIcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of technical feasibility for Homologous Recombination (HR) genes variants research on circulating tumor DNA (ctDNA) from plasma and urine of patients with a metastatic prostate cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor DNA | — | UNRESOLVED | — |
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Other | — | UNRESOLVED |
| Urine sample | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- adult patients with metastatic prostate cancer
- interventionNames
- Other: Blood sample
- Other: Urine sample
Primary outcomes (3)
- measure
- Circulating plasma tumour DNA
- timeFrame
- Baseline
- description
- search for somatic variants of HRR genes (including BRCA1/BRCA2)
- measure
- Circulating urine tumour DNA
- timeFrame
- Baseline
- description
- search for somatic variants of HRR genes (including BRCA1/BRCA2)
- measure
- FFPE tissue
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria * Age \> 18 years * Metastatic prostate cancer * Archived tissue sample available for testing for somatic variants of HRR genes (including BRCA1/BRCA2) * Free, informed and signed consent for research Non inclusion criteria * Refusal of blood and urine collection * Patient cognitively incapable of signing consent to participate in this study * Patient under guardianship or curatorship
References
Publications (0)
Data not yet available
No reference posted for this study.